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Abstract
Inhaled corticosteroids (ICS) are the most effective therapy for asthma currently available. The increasing use of ICS 
raises the issue of possible adverse systemic effects. Since one of the most important side-effects of oral corticosteroids 
(OCS) is osteoporosis, this article focuses on current knowledge of the effects of ICS on bone. Generally, doses higher than 
1.0 mg/day cause a dose-dependent decrease in serum osteocalcin levels. Decreases in bone density have been suggested 
after treatment with ICS, but in most studies it is impossible to quantify the contribution of previous treatment with OCS and 
other confounding factors to bone loss. The clinical relevance of the observed changes in the long term is unknown. To date, 
no fracture data have been reported in patients, Beclomethasone dipropionate, budesonide and fluticasone propionate do not 
appeal* to be different per milligram ICS. In general, the lowest clinically efficacious dosage of ICS should be aimed at,
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1. Introduction
Bronchial asthma is a frequently occurring dis­
ease, affecting about 5% of the adult population and 
10-15% of children [l]. Inhaled corticosteroids (ICS) 
are the most effective therapy for asthma currently 
available [2,3]. These agents suppress the chronic 
inflammatory process, which is a pathological hall­
mark of this disease in the airways [3,4],
ICS are effective in various types of asthma and 
at all ages [2-4], The international consensus recom­
mends ICS to be used in an early stage of asthma 
[5-7], as airway inflammation is also present in 
patients with mild symptoms. In addition, there is a 
tendency to prescribe ICS for a prolonged period of
* Corresponding author. Tel.: +31 24 3614579; fax: +31 24 
3540788.
time, as even after 2 years of treatment no plateau 
has been reached in effects [6-8]. Finally, there may 
be a dose-related improvement, since increasing the 
dose of ICS results in a greater improvement in the 
patients [9]. High-dose ICS may be used to control 
severe asthma and to reduce the need for oral corti­
costeroids (OCS) [10,11]. In Europe, the ICS mostly 
used are beclomethasone dipropionate (BDP), budes­
onide (BUD), and fluticasone propionate (FP).
In line with the above-mentioned arguments, the 
international guidelines recommend ICS in an early 
stage of asthma, and there is a clear tendency to 
prescribe ICS for a prolonged period of time and at 
high doses. This change in prescription raises the 
issue of safety and potential adverse systemic effects. 
Indeed, high dosages are associated with systemic 
effects, such as adrenocortical suppression [4], and, 
in children, decrease of growth [12]. The other poten­
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tially serious side-effect of ICS concerns bone 
metabolism and bone quality in the long term [13]. 
Osteoporosis is one of the most important side-ef- 
fects of long-term treatment with OCS [14]. In this 
review we will focus on the currently known effects 
of ICS on bone.
2. Side-effects: general considerations
Only 10-15% of an inhaled dose of ICS reaches 
the target cells in the lower airways. The remaining 
part stays in the inhaler or is deposited in the oropha­
ryngeal cavity. This may cause local side-effects, 
such as dysphonia and oral candidiasis [15]. The 
incidence of thrush varies from 5 to 20%, and is 
related to the dose of ICS. Dysphonia is a much 
more common problem and may be due to local 
myopathy of laryngeal muscles [16],
The amount of ICS that reaches the systemic 
circulation, and therefore causes the systemic side- 
effects, is derived mainly (>  80%) from the part of 
ICS that is absorbed from the lung. The remainder 
comes from the fraction deposited in the oropharynx, 
which is swallowed and subsequently absorbed via 
the gastrointestinal tract [17]. The amount of ICS that 
reaches the systemic circulation in this way is small 
as a result of rapid biotransformation in the liver 
[18], and can be further reduced by the use of a large 
volume spacer or by mouth rinsing.
3, Effects of steroids on bone
tion, reflected in an increase in urinary Ca/creatinine 
and hydroxyproline/creatinine ratios [20,23] (Fig. 
l). These changes lead to secondary osteoporosis and 
a rise in (non-traumatic) fracture incidence [19,20,24].
ICS interact with the same glucocorticoid recep­
tors, and would therefore be expected to act along a 
similar pathway after systemic absorption. No signif­
icant effects on calcium or phosphate metabolism, 
however, were observed in adults in doses up to 
2.4-3.2 mg/day for short periods of time [14,25]. 
Similarly, no changes were found in children treated 
with doses up to 0.8 mg/day [26,27].
Indices of bone formation, such as alkaline phos­
phatase (AP) or the bone-specific isoenzyme of AP, 
were not altered by ICS in most studies [25-31]. 
Only in the study of Ali et al. were changes found 
[32]. In this study in 8 healthy volunteers, a small 
decrease in AP was found after treatment with BDP
2.0 mg/day for 4 weeks, whereas after BUD 1.8 
mg/day (n — 8) no changes were observed. The 
significance of this open and small study is further­
more limited because of inaccurate statistical analy­
sis, Kerstjens et al. [33] found no differences in AP 
after 4 weeks treatment with at least 0.8 mg of BDP 
or BUD.
In contrast, studies with a wash-out or placebo 
period, or with a control group without ICS, showed 
a dose-dependent decrease of the serum osteocalcin 
level, currently the most commonly used marker of 
bone formation [34] (Fig. 2) [21,25-31,35-38]. Os­
teocalcin is a very sensitive marker of osteoblast 
activity, as most serum osteocalcin originates from 
new cellular synthesis [34]. Osteocalcin is a specific 
marker of bone formation in processes with uncou-
3.1. Biochemical markers of bone turnover
One of the most important side-effects of corticos­
teroids is osteoporosis. Osteoporosis may affect up to 
50% of patients on maintenance treatment with OCS 
[19]. OCS inhibit the intestinal absorption of calcium 
(Ca) and phosphate and may increase urinary Ca 
excretion. The resulting decrease in serum Ca evokes 
secondary hyperparathyroidism, which is reflected in 
an increased serum level of PTH [20]. OCS also 
decrease bone formation, as reflected by a decrease 
in alkaline phosphatase, osteocalcin and procollagen 
type 1 carboxy-terminal propeptide (P1CP) [20-23]. 
In addition, OCS possibly also increase bone resorp-
SEX HORMONE 
PRODUCTION 
in adrenal gland 
& laatis +
GLUCOCORTICOSTEROIDS
OSTEOBLAST OSTEOCLAST PARATHYROID Ca-ABSORPTION 
ACTIVITY *  ACTIVITY t ACTIVITY t  in gastrointest.tract +
t
BONE FORMATION 7
OSTEOPOROSIS
Fig. 1. Overview of the effects of oral corticosteroid (OCS) and 
inhaled corticosteroids (ICS) on bone metabolism and bone struc­
ture. Solid arrows =  OCS; dotted lines = ICS.
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Fig. 2. Changes in serum osteocalcin level as a result of inhaled 
corticosteroids (ICS) and equipotent doses of oral corticosteroids 
(OCS). O  =  budesonide; 0  =  beclomethasone dipropionate; O  
=  fluticasone propionate; a  =  oral prednisone. The symbols 
represent the outcomes in different studies [21,25-31,35-38],
[39]. Changes in trabecular bone are better reflected 
in the concentration of cross-links, and deoxypyridi- 
noline is more specific for osseous tissue than are 
pyridinoline cross-links [34]. To date, only a few 
data are available on the effects of ICS on pyridino­
line excretion in asthmatic patients, showing no 
changes [31,45]. Altogether, these findings indicate 
that in general ICS do not increase bone resorption.
The long-term effects of ICS on bone metabolism 
are unclear, Kerstjens and colleagues [33] reported 
that long-term treatment with ICS did not affect 
biochemical markers of bone metabolism. PI CP and 
1CTP remained unchanged after 2.5 years of treat­
ment with 0.8 mg BDP daily. Long-term studies with 
higher dosages of ICS have not been reported to our 
knowledge.
pled bone formation and resorption, as is the case in 
glucocorticoid-induced osteoporosis [34,39].
No differences between BDP, BUD and FP ap­
pear to exist. From the same studies, effects of 
'systemic equivalent doses' of OCS [40] are included 
in Fig. 2, showing the advantage of ICS. However, 
when looking at comparative trials between FP in 
half the dose of BDP, being clinically equipotent 
[41,42], osteocalcin levels were significantly lowered 
after the double dose of BDP, with no change after 
FP [31,43]. Ayres et al. [44] compared FP with BUD, 
but all patients already used 1-2 mg of ICS daily 
before the study. FP 1.0 and 2.0 mg, and BUD 1.6 
mg daily did not change osteocalcin levels signifi­
cantly. New markers of bone formation such as 
collagen type I extension peptides (P1CP) have 
shown no clear advantage over osteocalcin [34].
Markers of bone resorption, such as excretion of 
calcium and hydroxyprolines in urine, appeared to be 
increased in one study [32], but were unaltered in 
most studies [21,25,26,30,31,33,37]. Other markers 
of bone resorption include type 1 carboxy-terminal 
telopeptide (1CTP) and (deoxy)pyridinoline cross­
links [34,39]. 1CTP measures the degradation of 
mature type I collagen (containing pyridinoline 
cross-links). 1CTP has been found to increase in 
diseases that degrade the surface (cortical part) of 
bone tissue (e.g., rheumatoid arthritis, bone metasta­
sis), and changes only a little when trabecular bone 
is affected as in the case of glucocorticoid therapy
3.2. Bone mineral density
Low bone mass is an essential feature of osteo­
porosis. The clinical diagnosis of osteoporosis re­
quires the presence of at least one atraumatic fracture 
[46]. Measuring bone mineral density - by different 
techniques at different sites - is of prognostic rele­
vance. In general, a reduction in bone mineral den­
sity by one standard deviation increases the risk of a 
fracture by 50-100% [47].
OCS in doses of 7.5 mg/day or more cause 
significant loss of bone in most patients, with a 
significantly greater loss of trabecular than of corti­
cal bone. There is a relationship between rate of 
bone loss and OCS dose, with bone loss of up to 8% 
per year in doses of 8-17 mg/day and up to 17.5% 
in doses up to 25 mg/day [48]. However, lower 
doses of OCS may also have increased rates of bone 
loss [48,49]. Data suggest that bone loss is most 
pronounced in the early weeks of OCS therapy with 
subsequent slowing during prolonged treatment [48]. 
Up to 50% of patients on maintenance treatment 
with OCS may experience (non-traumatic) fractures
in the long term [19,20,24,48].
Reductions in bone mineral density have also 
been suggested after treatment with ICS. Only a few 
studies have been conducted in patients who had 
previously (virtually) not been treated with OCS. A 
group of 26 children who had used ~ 0.6 mg (range 
0.4-0.8) BDP daily for a period of 2 years showed
G.P. Bootsma et al. /  Netherlands Journal of Medicine 50 (1997) 254-260 257
no changes compared to a control group [27]. On the 
other hand, a cross-sectional study in a group of 18 
adult asthmatics, treated with at least 0.8 mg BDP or 
BUD for 1 year, showed a significant reduction in 
Z-score of the femoral head, compared with 18 
asthmatics never having used ICS [13]. Serum osteo­
calcin was also significantly lower in the ICS-treated 
group than in the asthma control group. Again, there 
were no changes in AP or in urinary pyridinoline and 
deoxypyridinoline. Dose and duration of treatment 
with ICS correlated negatively with bone mineral 
density.
Most studies examining changes in bone mineral 
density in patients with asthma are flawed because of 
failure to control for previous OCS use [46,50,51]. In 
other studies, the dose of ICS was probably too low 
to cause changes [52,53]. The previous use of OCS, 
however, may be the most important factor influenc­
ing bone mineral density, besides other factors such 
as increased age, inactivity, smoking, malnutrition, 
menopausal status and genetic predisposition. Fi­
nally, asthma itself may lower bone mineral density
[45].
Recently, Pauwels et al. [43] demonstrated that 
changing existing therapy with ICS (either BDP of 
BUD) to half the dose with FP resulted in a signifi- 
cant recovery of trabecular bone mineral density in 
Ward’s triangle. This would be a confirmation that 
ICS really affect bone. Extensive data in this respect, 
however, have to be awaited.
3.3. Comparison between BDP, BUD and FP
The risk/benefit ratio of inhaled steroids is deter­
mined by the ratio of local (airway) efficacy versus 
systemic glucocorticoid activity. There are clear dif­
ferences between the existing ICS with respect to 
pharmacokinetic properties. In the lung, BDP is 
hydrolysed to its much more active metabolite, be- 
clomethasone-17-monopropionate (17-BMP) [54]. 
Metabolism of BUD and FP does not occur in the 
lung [38,55]. Systemic effects may also arise from 
absorption of the drugs from the oropharynx and 
from the gut after swallowing. ICS have an extensive 
first-pass metabolism in the liver, converting the ICS 
into hardly active or non-active metabolites. BUD is 
transformed 2-4 times more rapidly than 17-BMP, 
with an oral systemic bioavailability of 11% [55].
The hepatic excretion ratio of FP is almost 100%, 
resulting in an oral bioavailability of < 1% [56].
In models of inflammation, BUD showed a 2-4 
times higher local anti-inflammatory activity than
BDP [57,58], FP showed twice the activity of BDP 
and BUD in one study, another found no significant 
differences between FP and BUD [59,60]. However, 
the extent to which these differences are also of 
clinical importance must be deduced from studies 
comparing these drugs on relevant parameters. With 
regard to clinical efficacy of BDP and BUD, no 
differences were shown over a wide dosage interval 
(0.4-1.5 mg), when compared in similar dosages and 
forms of administration, both in adults [11,61-66] 
and in children [67-69]. Even with different dosages 
and a difference in deposition in the airways, these 
studies also did not show any difference in clinical 
efficacy between the two preparations. The majority 
of comparable trials of FP (although mostly assessed 
against BDP) confirm preclinical data suggesting a 
higher clinical potency of FP over a wide dosage 
range (for review, see [41,70]).
With regard to the systemic effects, the negligible 
oral bioavailability of FP compares favourably with 
the other ICS. However, as the majority of the 
systemic available dose reaches the bloodstream af­
ter absorbtion from the lungs, assessment of overall 
systemic activity remains necessary. There appear to 
be no differences in systemic effects of the 3 ICS in 
equal dosages (Fig. 2). However, there appears to be 
a clear dose-related increase in systemic effects. As 
FP on a milligram base is more potent than BDP 
(and possibly BUD [70], this offers the ability to 
deliver lower dosages with similar clinical efficacy, 
leading to less effect on bone structure and 
metabolism.
4. Conclusion
The short- and long-term clinical efficacy of ICS 
in asthmatics has now been proved convincingly. 
With regard to higher dosages, it cannot be excluded 
that these drugs have adverse effects on bone in the 
long term. Dose-dependent changes in parameters of 
bone metabolism indicate systemic effects in the 
short term, but the course after long-term treatment 
is unknown. Furthermore, the relationship of these
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changes to bone quality is speculative. It still needs 
to be determined whether changes in bone turnover 
actually signify an increased fracture risk in the long 
term, To date, this has not been observed in clinical 
practice. Clearly, more controlled studies are needed 
since no definitive answer has been given. Measur­
ing indices of bone metabolism and bone mineral 
density in patients treated with only ICS should not 
be used so far in clinical practice. Nevertheless, an 
increasing number of studies report effects of ICS on 
bone. In this respect, the lack of short-term effects 
on bone metabolism by FP, in contrast to clinically 
equipotent dosages of BDP, may be of potential 
interest.
In the meantime, caution is desirable when admin­
istering high dosages of ICS over a long period of 
time, since there are differences in individual sensi­
tivity to ICS. The lowest possible dosage of ICS that 
has a clinically optimal effect on symptoms, lung 
function and bronchial hyperresponsiveness should 
be aimed at.
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